Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Tracy L. Rose

Hematology | Oncology
UNC Health
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
Accepting New Patients
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
UNC Health
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tracy Rose is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Rose is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Adrenal Cancer, Nephrectomy, and Tissue Biopsy. Dr. Rose is currently accepting new patients.

Her clinical research consists of co-authoring 63 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Johnston Health
Rex Hospital
Unc Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
101 Manning Dr, Chapel Hill, NC 27514
Call: 984-974-1000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer
Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug
Study Drugs: Pembrolizumab, Entinostat
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Enrollment Status: Completed
Publish Date: April 20, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
View 5 Less Clinical Trials

63 Total Publications

Engagement in cancer clinical trials among a nationally representative cancer survivor sample: Motivators, barriers and opportunities for improvement.
Engagement in cancer clinical trials among a nationally representative cancer survivor sample: Motivators, barriers and opportunities for improvement.
Journal: Tumori
Published: June 12, 2025
View All 63 Publications
Similar Doctors
Daniel J. George
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Daniel J. George
Urology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Daniel J. George
Urology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (9.5 miles away)
919-681-6900
Experience:
33+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

I specialize in the care of patients with urologic cancers – mainly prostate cancer, kidney cancer, bladder cancer and testicular cancer. A cancer diagnosis is one of the scariest things that can happen to someone. For many of our patients, they don’t necessarily feel different or look different, but they are scared to death. The most important thing you can get from Duke is real understanding of your particular case and what your options are. Knowledge is so reassuring and empowering for patients, especially those recently diagnosed with cancer. When you’re first diagnosed, you have to put your trust in a care team, and that’s hard to do if you don’t already know them. As the largest cancer center in North Carolina, Duke has great reputation and experience, which helps many patients chose Duke for their care. But we grow and develop our trust with patients because of who we are as people and how much expertise and care we bring to each case. Dr. George is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Michael R. Harrison
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael R. Harrison
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael R. Harrison
Oncology | Hematology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (9.5 miles away)
919-681-6900
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

I specialize in treating people with genitourinary (GU) cancers, such as bladder, prostate, testicular and kidney cancer. I don’t treat other types of cancer across the breadth of tumors like some oncologists in the community may, such as blood cancer, breast cancer or lung cancer. My focus has allowed me to gain deep expertise in GU cancers and to stay abreast of the newest treatment advances, clinical research and so on for those specific GU cancers. As a medical oncologist, I meet patients at one of the scariest moments of their lives. I try to help educate them to make a decision about their disease and its process, and what their treatment options may be, so we can come to a shared decision about what might be the best option. The teaching aspect really strikes home for me. Both of my parents are teachers. The root word for “doctor” in Latin means “to teach.” So that is something I’m both naturally called to do and enjoy doing. Dr. Harrison is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Prostatectomy.

Sundhar Ramalingam
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sundhar Ramalingam
Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sundhar Ramalingam
Hematology

Duke Cancer Center Cary

216 Ashville Ave, 
Cary, NC 
 (18.8 miles away)
866-385-3123
Experience:
15+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

I mainly treat patients with genitourinary cancers including prostate, kidney, bladder, testicular and penile cancer.  My goal is to be attentive and devoted to my patients who are often dealing with complicated health problems. I try to personalize my care because every patient is different. I believe the future is promising because new treatments are being discovered every day. I am involved in clinical trials done through Duke University.  Clinical trials are designed to provide patients with access to the newest possible treatments. I am also part of our multi-disciplinary cancer team including urologic oncologists, geneticists, radiation oncologists, pathologists, radiologists, and other specialists.  I grew up in Cary and did all of my medical training in the Research Triangle Park area. I feel honored to practice in the same community I have lived in for more than twenty-five years. Dr. Ramalingam is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, and Prostatectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rose's expertise for a condition
ConditionClose
    • Distinguished
    • Adrenal Cancer
      Dr. Rose is
      Distinguished
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Bladder Cancer
      Dr. Rose is
      Distinguished
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Prostate Cancer
      Dr. Rose is
      Distinguished
      . Learn about Prostate Cancer.
      See more Prostate Cancer experts
    • Renal Cell Carcinoma (RCC)
      Dr. Rose is
      Distinguished
      . Learn about Renal Cell Carcinoma (RCC).
      See more Renal Cell Carcinoma (RCC) experts
    • Urothelial Cancer
      Dr. Rose is
      Distinguished
      . Learn about Urothelial Cancer.
      See more Urothelial Cancer experts
    • Advanced
    • Adrenocortical Carcinoma
      Dr. Rose is
      Advanced
      . Learn about Adrenocortical Carcinoma.
      See more Adrenocortical Carcinoma experts
    • Adult Soft Tissue Sarcoma
      Dr. Rose is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Rose is
      Advanced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Rose is
      Advanced
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Familial Prostate Cancer
      Dr. Rose is
      Advanced
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Familial Wilms Tumor 2
      Dr. Rose is
      Advanced
      . Learn about Familial Wilms Tumor 2.
      See more Familial Wilms Tumor 2 experts
    View All 11 Advanced Conditions
    • Experienced
    • Choriocarcinoma
      Dr. Rose is
      Experienced
      . Learn about Choriocarcinoma.
      See more Choriocarcinoma experts
    • Hereditary Neuroblastoma
      Dr. Rose is
      Experienced
      . Learn about Hereditary Neuroblastoma.
      See more Hereditary Neuroblastoma experts
    • Hypothalamic Hamartomas
      Dr. Rose is
      Experienced
      . Learn about Hypothalamic Hamartomas.
      See more Hypothalamic Hamartomas experts
    • Inflammatory Myofibroblastic Tumor
      Dr. Rose is
      Experienced
      . Learn about Inflammatory Myofibroblastic Tumor.
      See more Inflammatory Myofibroblastic Tumor experts
    • Mediastinal Tumor
      Dr. Rose is
      Experienced
      . Learn about Mediastinal Tumor.
      See more Mediastinal Tumor experts
    • Melanoma
      Dr. Rose is
      Experienced
      . Learn about Melanoma.
      See more Melanoma experts
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved